-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5837 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5837 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5837 in Diffuse Large B-Cell Lymphoma Drug Details: REGN-5837 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Izalontamab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Izalontamab in Hypopharyngeal Cancer Drug Details: SIB-001 is under development for the...
-
Product Insights
Binge Eating Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Binge Eating Disorder - Drugs In Development, 2023’, provides an overview of the Binge Eating Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Binge Eating Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Appetite (Eating) Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Appetite (Eating) Disorders - Drugs In Development, 2023’, provides an overview of the Appetite (Eating) Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Appetite (Eating) Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVN-424 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVN-424 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CVN-424 in Parkinson's Disease Drug Details: CVN-424 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVN-293 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVN-293 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CVN-293 in Alzheimer's Disease Drug Details: CVN-293 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVN-293 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CVN-293 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CVN-293 in Amyotrophic Lateral Sclerosis Drug Details: CVN-293 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVN-766 in Schizophrenia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVN-766 in Schizophrenia Drug Details: CVN-766 is under development for the treatment of anxiety disorders,...